Cargando…
Pharmacokinetics, distribution, and excretion of sodium oligomannate, a recently approved anti-Alzheimer's disease drug in China
The National Medical Products Administration has authorized sodium oligomannate for treating mild-to-moderate Alzheimer's disease. In this study, an LC-MS/MS method was developed and validated to quantitate sodium oligomannate in different biomatrices. The plasma pharmacokinetics, tissue distri...
Autores principales: | Lu, Jiaojiao, Pan, Qiongqun, Zhou, Jieqiang, Weng, Yan, Chen, Kaili, Shi, Lv, Zhu, Guanxiu, Chen, Chunlin, Li, Liang, Geng, Meiyu, Zhang, Zhenqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Xi'an Jiaotong University
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073255/ https://www.ncbi.nlm.nih.gov/pubmed/35573885 http://dx.doi.org/10.1016/j.jpha.2021.06.001 |
Ejemplares similares
-
A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia
por: Wang, Tao, et al.
Publicado: (2020) -
Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression
por: Wang, Xinyi, et al.
Publicado: (2019) -
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia
por: Xiao, Shifu, et al.
Publicado: (2021) -
Sodium oligomannate combined with rivastigmine may improve cerebral blood flow and cognitive impairment following CAR-T cell therapy: A case report
por: Wang, Yan-Li, et al.
Publicado: (2022) -
The Pharmacokinetics of The Biliary Excretion of Ciprofloxacin
por: Ball, C. S., et al.
Publicado: (1989)